

## ASX Release

---

# Company Secretary

**PERTH, AUSTRALIA – 18 August 2020:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that Phillip Hains has taken over as Company Secretary.

Mr Phillip Hains became Joint Company Secretary on 1 July 2020. Phillip is a chartered accountant operating a specialist public practice, The CFO Solution. A specialist in the public company environment, Phillip has served the needs of a number of company boards and their related committees. He has over 25 years' experience in providing businesses with accounting, administration, compliance and general management services. He holds a Master of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants.

Mr Joseph Ohayon, who joined the company in July 2010, held the role as Company Secretary from March 2011 and had been a director of the company from December 2012 until May 2019. He has assisted in the transition of accounting and company secretarial services to The CFO Solutions and supported Dr Michael Baker since Michael joined at the beginning of the year.

Joseph will be leaving the company at the end of September. During his time at SUDA, he has provided invaluable contributions to the company. The team at SUDA wish Joseph all the best for his new endeavours.

For and on behalf of the Board and for further information please contact:

**Paul Hopper**  
**Chairman**  
**SUDA Pharmaceuticals Ltd**  
Tel: +61 (0) 406 671 515  
phopper@sudapharma.com

**Dr Michael Baker**  
**Chief Executive Officer & Managing Director**  
**SUDA Pharmaceuticals Ltd**  
Tel +61 (0) 403 468 187  
mbaker@sudapharma.com

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)